CytomX Therapeutics, Inc. (NASDAQ:CTMX) has been given a $37.00 price target by research analysts at Wedbush in a research note issued on Wednesday. The firm currently has a “buy” rating on the biotechnology company’s stock. Wedbush’s price objective suggests a potential upside of 67.72% from the company’s previous close. Wedbush also issued estimates for CytomX Therapeutics’ Q1 2018 earnings at ($0.21) EPS, Q2 2018 earnings at ($0.24) EPS, Q3 2018 earnings at ($0.27) EPS and Q4 2018 earnings at ($0.30) EPS.

Other analysts also recently issued research reports about the stock. Cowen and Company reissued a “buy” rating on shares of CytomX Therapeutics in a research note on Tuesday, August 8th. BidaskClub raised shares of CytomX Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. Bank of America Corporation reaffirmed a “buy” rating and set a $30.00 target price (up from $28.00) on shares of CytomX Therapeutics in a research report on Wednesday, August 9th. ValuEngine lowered shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, September 15th. Finally, Jefferies Group LLC set a $25.00 price objective on shares of CytomX Therapeutics and gave the company a “buy” rating in a report on Friday, August 25th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $32.67.

CytomX Therapeutics (CTMX) traded down 4.46% during midday trading on Wednesday, reaching $22.06. The company had a trading volume of 650,923 shares. The company’s market capitalization is $813.29 million. The firm has a 50-day moving average price of $17.15 and a 200-day moving average price of $15.67. CytomX Therapeutics has a 52 week low of $9.85 and a 52 week high of $24.67.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.39) by ($0.30). The firm had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $4.95 million. CytomX Therapeutics had a negative net margin of 206.33% and a negative return on equity of 84.61%. Analysts expect that CytomX Therapeutics will post ($1.47) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Wedbush Analysts Give CytomX Therapeutics, Inc. (CTMX) a $37.00 Price Target” was reported by Watch List News and is the sole property of of Watch List News. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece of content can be accessed at https://www.watchlistnews.com/cytomx-therapeutics-inc-ctmx-receives-outperform-rating-from-wedbush/1610484.html.

In other CytomX Therapeutics news, insider Sean A. Mccarthy sold 4,781 shares of the business’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $15.00, for a total value of $71,715.00. Following the transaction, the insider now directly owns 9,026 shares in the company, valued at approximately $135,390. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Debanjan Ray sold 2,500 shares of the business’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $15.00, for a total transaction of $37,500.00. Following the completion of the transaction, the chief financial officer now owns 19,626 shares in the company, valued at $294,390. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 100,306 shares of company stock valued at $1,924,746. 4.70% of the stock is owned by corporate insiders.

Several hedge funds have recently modified their holdings of the company. FMR LLC lifted its holdings in shares of CytomX Therapeutics by 0.6% in the 2nd quarter. FMR LLC now owns 5,512,459 shares of the biotechnology company’s stock worth $85,444,000 after acquiring an additional 34,732 shares during the last quarter. Perceptive Advisors LLC lifted its holdings in CytomX Therapeutics by 65.7% during the 1st quarter. Perceptive Advisors LLC now owns 1,530,659 shares of the biotechnology company’s stock worth $26,434,000 after buying an additional 606,896 shares in the last quarter. Vanguard Group Inc. lifted its holdings in CytomX Therapeutics by 12.2% during the 2nd quarter. Vanguard Group Inc. now owns 924,138 shares of the biotechnology company’s stock worth $14,323,000 after buying an additional 100,607 shares in the last quarter. EcoR1 Capital LLC acquired a new stake in CytomX Therapeutics during the 1st quarter worth approximately $13,729,000. Finally, Redmile Group LLC lifted its holdings in CytomX Therapeutics by 2.4% during the 2nd quarter. Redmile Group LLC now owns 698,392 shares of the biotechnology company’s stock worth $10,825,000 after buying an additional 16,500 shares in the last quarter. Hedge funds and other institutional investors own 59.97% of the company’s stock.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage, oncology-focused biopharmaceutical company. The Company uses its Probody technology platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against difficult-to-drug targets. Its pipeline is focused on the development of therapies in a set of modalities: Probody cancer immunotherapies, Probody drug conjugates, T-cell engaging Probody bispecifics and ProCAR-NK cell therapies.

Analyst Recommendations for CytomX Therapeutics (NASDAQ:CTMX)

Receive News & Ratings for CytomX Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.